“I think that’s a key component of this, and you know we have done some work within our own health system within one EMR, and that’s exciting but really limited. And what Tempus was able to do is they really have created something that can go across multiple EMRs.” – Dr. Melina E. Marmarelis From an interview published by @ASCO AI in Oncology on the #ASCO26 study, "Multi-center prospective study evaluating an AI-enabled clinical decision support tool to improve biomarker testing in early-stage NSCLC." The study demonstrated clinically meaningful improvements in biomarker testing rates following the implementation of Tempus Next. bit.ly/4uByg5X

Multi-site validation of our ECG-AF software, which received U.S. Food and Drug Administration clearance for predicting the one-year risk of atrial fibrillation or flutter, was published in @hrs_journal. The study evaluated the Tempus ECG-AF software across three geographically distinct clinical sites and demonstrates the promising avenue for improving diagnosis that the application of AI to electrocardiogram interpretation offers. Read on: tempus.co/heart-rhythm-ecg

Tempus researchers sought to investigate how PRAME expression levels correlate with real-world survival outcomes when patients are treated with a combination of immunotherapy and chemotherapy in the first-line setting. Explore the analysis and its results in the Lens Library now: tempus.co/4u7wycB

Lines of therapy are a key anchor for benchmarking therapy performance and informing R&D strategy, including when comparing patient outcomes and drug effectiveness over time and across cohorts. In a new article we detail the expert-vetted, rules-based approach to standardizing line of therapy capture for #oncologyresearch. This standardized foundation enables researchers to proceed directly to analysis with confidence. Read now: tempus.co/4aiujMi

So proud to see two of the top pharmaceutical CEOs in the world, Pascal Soriot, CEO of @AstraZeneca, and Rob Davis, CEO of @Merck, recently highlight their strategic partnerships with Tempus to bring the power and promise of artificial intelligence to oncology. bit.ly/4ofFHOF bit.ly/4vBGgVD

Our single, research-ready dataset gives you a complete picture by unifying connected clinical histories, rich multimodal biology, and a representative patient population. Assess your cohort’s feasibility with our RWD by submitting your preliminary criteria, and our team will provide a tailored feasibility assessment to help accelerate your research goals: tempus.co/4uduyzn

#ASCO26 has come to a close and we're grateful for an impactful weekend in Chicago spent with colleagues and the greater oncology community. Check out some highlights below, including the presentations of our largest collection of accepted research to date, an engaging Industry Expert Theater, and four days of conversations and demos at our booth. You can find more information about our presence at ASCO here: tempus.co/3RZyVAD

Together with @YNHH and @MSKCancerCenter, we are pleased to announce the launch of a digital pathology IMS Open-Source Consortium. Designed to accelerate the democratization and standardization of digital pathology, the consortium aims to bring together leading academic medical centers and industry partners to develop a best-in-class open-source digital pathology platform and viewer. Read on: tempus.co/3PCH7WY

We're excited to announce the upcoming clinical availability of xH, a next-generation sequencing test that uses a whole-genome sequencing approach for the detection of actionable oncologic targets in peripheral blood and bone marrow samples from patients with hematologic malignancies. Data presented at #ASCO26 demonstrate the assay's clinical utility in resolving historical diagnostic blind spots. Learn more: tempus.co/4o1YTQ5

Meet the next-generation of Lens, our pioneering agentic AI platform designed to accelerate drug development and research. Specialized tools include: ▪️ Custom Research Plan Generation ▪️ On-Demand Execution ▪️ Specialized AI Agents ▪️ Reproducible Intelligence Read on: tempus.co/3RxmUCu

Test selection matters, esp in genomics - HLA can be tested in tumor, blood with different mechanisms for false - and ➡️high tumor purity and LOH lead to most false - ➡️blood sometimes needed when tumor QC is low at locus of interest ➡️bioinformatics algos matter #ASCO26

We're excited to share the launch of the PRECISION Challenge: a national initiative engineered to accelerate the next generation of oncology breakthroughs leveraging its foundational model. The PRECISION Challenge aims to unlock breakthroughs in oncology at scale by providing access to data, funding, and expertise to multidisciplinary teams around the world who seek to make bold advances in cancer treatment and improve patient outcomes. We will announce the opening of applications for the inaugural cohort in the coming months. Learn more: tempus.co/4dSHNPX #ASCO26

#ASCO26: Don't miss our Industry Expert Theater this afternoon in Theater 2, Exhibit Hall A from 3:00 pm – 4:00 pm CT. Our Chief Scientific Officer, Kate Sasser, PhD, will join our Chief Medical Officer, Ezra Cohen, MD to explore how our comprehensive diagnostic intelligence platform transforms vast datasets into insights to ensure that no patient is left behind in the pursuit of better outcomes.

Introducing Tempus Preview: an application providing rapid, clinically significant insights that close the gap between the time of order and delivery of insights. Representing a significant paradigm shift in precision oncology workflows, Tempus Preview offers preliminary results in the critical window between when a diagnostic test is ordered and when final sequencing results are delivered by surfacing key mutation predictions within approximately 24 hours of tissue receipt. Learn more: tempus.co/3PUFnYZ #ASC026

Thank you to all who joined us today. The full recording and presentation deck are now available: edge.media-server.com/mmc/p/… #TEMInvestorDay

We're proud to announce that the U.S. Food and Drug Administration (FDA) has granted approval for a tumor-only indication for our xT CDx next-generation sequencing platform. With this expanded label, Tempus is the first laboratory to hold FDA companion diagnostic (CDx) approval for both tumor-only and tumor-normal comprehensive genomic profiling. Read on: tempus.co/4eaJ9Xr #ASCO26 *xT CDx is a qualitative Next Generation Sequencing (NGS)-based in vitro diagnostic device intended for use in the detection of substitutions (single nucleotide variants (SNVs) and multi-nucleotide variants (MNVs)) and insertion and deletion alterations (INDELs) in 648 genes in patients with previously diagnosed solid malignant neoplasms. The assay uses DNA isolated from Formalin-Fixed Paraffin Embedded (FFPE) tumor tissue specimens and, when available, patient-matched blood or saliva specimens. Additionally, the device detects microsatellite instability (MSI) status based on a genomic signature from the tumor specimen only. The test is intended as a companion diagnostic (CDx) to identify patients who may benefit from treatment with the targeted therapies listed in the Companion Diagnostic Indications table in accordance with the approved therapeutic product labeling. Additionally, xT CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with previously diagnosed solid malignant neoplasms. Genomic findings other than those listed in the Companion Diagnostic Indications table are not prescriptive or conclusive for labeled use of any specific therapeutic product.